You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 7,763,256

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,763,256

Title:	Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
Abstract:	The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
Inventor(s):	Gomer; Richard (Houston, TX), Pilling; Darrell (Pearland, TX)
Assignee:	William Marsh Rice University (Houston, TX)
Application Number:	11/535,636
Patent Claims:	1. A method of suppressing fibrocyte formation in a mammal suffering from pulmonary fibrosis, the method comprising administering to a mammal in need thereof an amount of Serum Amyloid P (SAP) protein, or portion thereof, said portion comprising one or more sequences selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 sufficient to suppress pulmonary fibrosis, wherein the SAP or portion thereof binds to Fc.gamma. receptors and inhibits fibrocyte differentiation from monocytes. 2. The method of claim 1, wherein the SAP or portion thereof has a concentration in the composition of at least approximately 0.5 .mu.g/ml. 3. The method of claim 1, wherein administering the composition comprises administering by intravenous injection. 4. The method of claim 1, wherein the mammal is a human. 5. The method of claim 1, wherein said SAP or a portion thereof is conjugated to a biocompatible polymer. 6. The method of claim 5, wherein the biocompatible polymer is selected from the group consisting of PEG, a poly(amino acid), and a polysaccharide; or copolymers and combinations thereof. 7. The method of claim 1, further comprising administering a composition selected from the group consisting of IL-12, Laminin-1, IgG aggregates, cross-linked IgG and combinations thereof. 8. The method of claim 1, wherein administering comprises administering approximately 1.6 .mu.g SAP or a portion thereof per gram of bodyweight of the mammal. 9. The method of claim 1, wherein administering comprises administering an amount of SAP or a portion thereof sufficient to approximately double the normal serum concentration of SAP or a portion thereof similar to the portion thereof administered in the mammal. 10. The method of claim 1, wherein administering comprises administering an amount of SAP sufficient to increases the normal serum concentration of SAP or the a portion thereof similar to the portion thereof administered in the mammal by approximately 25%. 11. The method of claim 1, wherein the SAP protein or a portion thereof forms a pentamer. 12. The method of claim 1, wherein administering comprises administering the SAP protein or a portion thereof an amount of approximately 600 .mu.g or more. 13. The method of claim 1, wherein pulmonary fibrosis comprises a condition selected from the group consisting of: Adalimumab-associated pulmonary fibrosis, pulmonary interstitial fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, asthma, chronic obstructive pulmonary disease, diffuse alveolar damage disease, pulmonary hypertension, neonatal bronchopulmonary dysplasia, and emphysema.

Details for Patent 7,763,256

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2022-12-23
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2022-12-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.